Caris Life Sciences, Inc.

Caris Life Sciences, Inc.

Healthcare

NASDAQ:CAI · NASDAQ Global Select

Market Cap $5.08B Beta 0.79 P/E (TTM) 149.4
$17.97 -0.17%

-$0.03 today

52W Low $14.19High $42.50

Vol 1.96M · Avg 2.67M

EPS (TTM)$0.12
Biotechnology

Management

Put operating results in leadership context

Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-93.2%

avg 0.5%

ROIC

4.5%

avg -20.0%

ROA

-47.8%

avg -22.2%

Analysis

ROIC is currently the strongest return metric at 4.5% versus its period average of -20.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Management

Key executives, compensation & ownership

Management
NameTitleCompensationTenureAgeShares OwnedOwnership %

David Dean Halbert

Chairman, Chief Executive Officer & Founder$4.95M70$2.57M0.91%

David Spetzler

President$1.33M49$2.57M0.91%

Brian J. Brille

Executive Vice Chairman & Executive Vice President$1.20M64$230,303.000.08%

J. Russel Denton

Senior Vice President, General Counsel & Secretary$736,848.0042$181,515.000.06%

George W. Sledge Jr.

Executive VP & Chief Medical Officer74$17,729.00<0.01%

Valeriy Domenyuk

Senior Vice President & Chief Technology Officer

Andreas S. Tsukada

Senior VP, President of Japanese Operations & Head of International

Luke Power

Senior Vice President, Chief Financial Officer & Chief Accounting Officer44$153,771.000.05%

Matthew Oberley

Senior VP, Chief Clinical Officer & Pathologist-in-Chief

Narendra Chokshi

Senior Vice President of Corporate Development

Ginger Appleberry

Senior Vice President, Deputy General Counsel & Chief Compliance Officer

Stephanie Thomas

Executive VP & Chief of Staff at Office of the CEO$153,771.000.05%

Jeremy O'Brien

Senior Vice President of Human Resources

Jim Abraham

Senior VP & Chief Innovation Officer

Milan Radovich

Senior Vice President & Chief Scientific Officer

Jon Mark Harmon

Senior Vice President & Chief Operations Officer$118,621.000.04%

Insider Trading

SEC Form 4 transactions — last 12 months

Management

Buys

3

$611,759.01

Sells

2

$1.65M

Net Sentiment

$1.04M

Net selling

Most Active

Power Luke Thomas

2 transactions

DateInsiderTypeSharesPriceValue
May 11, 2026

Vacirca Jeff L

Direct

Buy31.1K$16.15$501,426.45
Dec 11, 2025

Power Luke Thomas

Direct

Sell60.9K$26.56$1,616,443.74
Dec 11, 2025

Power Luke Thomas

Direct

Sell1.4K$27.16$38,017.56
Nov 7, 2025

Spetzler David Baxley

Direct

Buy400$23.85$9,540.00
Nov 7, 2025

Denton John Russel

Indirect

Buy4.2K$24.09$100,792.56

Analysis

Insiders reported 3 buys worth $611,759.01 and 2 sells worth $1.65M over the last 12 months. That adds up to net selling of $1.04M. Power Luke Thomas was the most active insider with 2 transactions.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr5yr3yr Fwd Est.
EPSN/AN/A+3.8%
-5.4% (16yr)5 analysts
RevenueN/AN/A+21.9%
+13.9% (16yr)5 analysts
Net IncomeN/AN/A+6.3%
+24.3% (16yr)5 analysts
EBITN/AN/A+14.7%
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at +21.9% over three years. Forward estimates point to Net Income at +24.3% (16yr), giving you a quick check on whether expectations are accelerating or cooling.

Who manages CAI?

Caris Life Sciences, Inc. (CAI) lists 16 active executives. The top listed executive is George W. Sledge Jr., Executive VP & Chief Medical Officer.

Are CAI insiders buying or selling?

Recent insider activity shows net selling of $117.90M.

Explore More

Continue the stock analysis

Jump to another research area for this company.